The surgical morbidity rate of 603 patients who underwent lymphadenect
omy after primary chemotherapy for clinical stages II and III testis c
ancer from 1982 to 1992 was reviewed. There were 144 complications in
125 patients (20.7%). The majority of patients (93%) had a tumor volum
e of greater than 5 cm. Five patients died 3 to 47 days postoperativel
y, for an operative mortality rate of 0.8%. Pulmonary complications we
re the most; frequent cause of severe morbidity: 6 patients had the ad
ult respiratory distress syndrome and 5 needed prolonged ventilation.
The underlying cause was a combination of bleomycin induced pulmonary
toxicity, and large volume retroperitoneal and pulmonary disease resec
ted in these patients. Limiting inspired oxygen concentration and peri
operative volume replacement are imperative to minimize bleomycin rela
ted pulmonary morbidity. Additional procedures, such as nephrectomy an
d colectomy, did not add to the morbidity rate. Among patients undergo
ing concomitant venacavectomy there was a higher occurrence of postope
rative chylous ascites. Most of the other complications (gastrointesti
nal, lymphatic, neurological and renal) were temporary and treated con
servatively. Perioperative management of the post-chemotherapy testis
cancer patient is different from that of the patient undergoing primar
y retroperitoneal lymphadenectomy. The latter operation is usually per
formed in physically fit patients and the surgical template of dissect
ion is of a smaller scale. Thus, the complications in this group are m
inor and without mortality. Specific technical considerations and diff
iculties are common to post-chemotherapy patients. Factors, such as la
rge volume of disease, post-chemotherapy desmoplastic reaction and ext
ensive retroperitoneal dissection, make these patients more prone to h
ave complications. Decreased pulmonary, renal and nutritional reserves
add to the surgical morbidity. Knowledge of possible pitfalls and the
ir causes can avoid unnecessary operative complications.